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Abstract
Psoriatic arthritis is a multigenic autoimmune disease that involves
synovial tissue, entheseal sites and skin, and that may result in signi-
ficant joint damage. Although there are no diagnostic tests for
psoriatic arthritis, research has identified consistent features that
help to distinguish the condition from other common rheumatic
diseases. Comparison of HLA-B and HLA-C regions in psoriatic
arthritis with those in psoriasis without joint involvement demon-
strates significant differences, such that psoriatic arthritis cannot be
viewed simply as a subset of genetically homogeneous psoriasis. T-
cell receptor phenotypic studies have failed to identify antigen-
driven clones, and an alternative hypothesis for CD8 stimulation
involving innate immune signals is proposed. Finally, imaging
studies have highlighted entheseal involvement in psoriatic arthritis,
and it is possible that entheseal-derived antigens may trigger an
immune response that is critically involved in disease pathogenesis.
Introduction
There has been considerable progress in advancing our
understanding and treatment of psoriatic arthritis (PsA), but
major challenges and paradoxes remain, and in some instances
these have become more clearly defined. It is our objective to
review, concisely and critically, some of these topics and
provide an interpretive framework.
Evidence is increasing that PsA is an autoimmune disease in
which the CD8+ T cell plays a central role. This review
highlights evidence supporting the following: autoimmune
features of the disease, including the genetic susceptibility
associated with class I human leukocyte antigen (HLA) genes
in the major histocompatibility complex (MHC); the finding of
a predominance of clonally expanded CD8+ T cells in the
synovial tissue and fluid [1]; the independence from
participation of CD4+ T cells, as indicated by the develop-
ment of PsA in the setting of advanced AIDS; the interesting
observation of PsA developing for the first time after syn-
geneic bone marrow transplantation from a psoriasis donor
[2]; and the response to therapeutic agents directed at
activated T cells (for example, DAB389IL-2 or alefacept), as
well as to effector pathways resulting from T-cell activation.
Autoantibodies are not detectable in PsA, distinguishing this
and the other class I associated diseases, such as ankylosing
spondylitis, from the autoimmune diseases associated with
class II MHC alleles, in which autoantibodies presumably
engendered through CD4+ T-cell help are conspicuous. As is
the case with all autoimmune diseases, the nature of the
peptide that drives the T-cell response remains unknown, and
some of the reasons for the difficulty of this identification in
PsA are mentioned.
In this review considerable stress is placed on important
insights resulting from the application of newer imaging
modalities. These modalities greatly expand the clinical
spectrum in PsA, and they assist in advancing the conceptual
framework of this disease and point to tissues and cell types
that might express driving autoantigens.
Genetic susceptibility
Compared with most other rheumatic diseases, heredity
plays a particularly strong role in the development of PsA.
About 15% of the relatives of an index patient with PsA will
also have PsA, and an additional 30% to 45% will have
psoriasis. Accordingly, the presence of either psoriasis or
PsA in a family member of a patient suspected of having PsA
provides support for the diagnosis. Identification of the genes
responsible for this high degree of familial aggregation
remains an ongoing process but, among the identified genes,
the HLA genes in the MHC are of primary importance in the
development of PsA. The patterns of inheritance of psoriasis
and PsA are those of a genetically complex multigenic
disease, and may range from those that simulate a dominant
mode of inheritance to families in which the illness appears to
have a recessive mode (Figure 1).
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It is increasingly being recognized that the genetic features of
PsA differ according to whether the case series is ascertained
in a rheumatology clinic, reflecting presentation as a musculo-
skeletal disorder, or whether it is ascertained in a dermatology
unit, where psoriasis patients with more severe skin disease
are first identified and then a subset with musculoskeletal
features is delineated after a decade or more of skin disease [3].
In contrast to most other autoimmune diseases in which
susceptibility is specified by HLA-DR or other class II MHC
genes, in PsA it is the class I genes, notably alleles at the
HLA-B and HLA-C loci, that are involved. These include the
HLA-C allele Cw*0602, which is the major determinant of
susceptibility to psoriasis, and the HLA-B alleles B*27 and
B*39, and possibly some additional alleles [3,4]. Ho and
coworkers [5], in a careful immunogenetic study, re-empha-
sized that HLA-DRB1*04 alleles encoding the shared epitope,
and strongly associated with susceptibility to rheumatoid
arthritis (RA), were not associated with PsA. Furthermore,
they showed that HLA-Cw*06 and  HLA-DRB1*07  were
indeed associated with patients with PsA having type I (onset
before age 40 years) but not type II psoriasis (onset after age
40 years). This report shows that patients with PsA who have
type I psoriasis have a genetic background different from
those with type II psoriasis and in turn from RA.
Ongoing analyses indicate that these several MHC alleles
operate independently in specifying the disease phenotype of
PsA. This suggests that there could be two genetic pathways
to PsA [3,4]. One is through the function of the HLA-B alleles
B*27 and B*39, and another is through the function of
haplotypes containing the HLA-C allele Cw* 0602 (Psors1).
Evidence is emerging that these two forms of PsA that share
the psoriasis phenotype are subtly different. It appears that
the Cw*0602 alleles confer a phenotype with more severe
skin disease and, on average, a long interval (≥10 years)
between the appearance of psoriasis and the development of
the musculoskeletal features of PsA. In those with B*27 or
B*39, the musculoskeletal component appears more
synchronously with the cutaneous component, and PsA is
more likely than in the presence of Cw*0602. The complex
relationship between these two different genetic substrates in
terms of developing PsA is illustrated in Figure 2.
This emerging genetic information has the potential to be
integrated into the challenge of validating the PsA diagnostic
criteria. These genetic advances, if applied to series of cases,
should also identify the misclassification as PsA of patients
with psoriasis who simply also have fibromyalgia, osteo-
arthritis or a repetitive motion injury.
In view of the high degree of familial aggregation and the
overall heritability of PsA, it is unlikely that the HLA genes
account for more than a portion of the genetic susceptibility.
There are likely to be non-MHC genes that specify important
aspects of the development of PsA.
Immunopathogenesis
The presence of susceptibility genes in an individual defines
the first preclinical stage of the development of PsA. The T-cell
Figure 1
Inheritance of psoriatic arthritis. Two families are shown in which psoriatic arthritis (half-filled shapes) appears to exhibit a different pattern of
inheritance. In the first it appears that the disease is inherited as a simple dominant, although the absence of disease in the parents is not
consistent with this. In the second, there is an interplay between the psoriasis phenotype (quarter-filled shapes) in the parent and child in the third
generation, and the instances of psoriatic arthritis in the second.repertoire that is developed on the individual’s self-peptides
and self-MHC is poised for autoreactivity, but remains
quiescent until triggered. Once triggered the immune
process results in the development of the two main features
of PsA: the inflammatory infiltrate of T cells and accessory
cells into the entheses and synovium, and the response of the
synovial and entheseal tissues to the products and
consequences of the inflammatory infiltrate. These alterations
are summarized in this section of the review.
Some insight into the immune and pathogenetic events that
underlie PsA came from an unexpected source. During the
early stages of the HIV pandemic the de novo appearance of
PsA and of reactive arthritis in those with advanced loss of
CD4+ T cells was an experiment of nature that distinguished
these two spondyloarthritis disorders from most other rheu-
matic diseases such as RA and systemic lupus erythe-
matosus, which were ameliorated by the loss of CD4+ T cells.
This occurrence directed attention to the possibility that the
pathogenesis of PsA differed substantively from that of RA
and systemic lupus erythematosus. It emphasized that, in the
pathogenesis of PsA, one had to consider the role of CD8+
T cells activated by the innate immune system, as well as
elevated cytokines and triggering by persisting microbes.
Biology of MHC class I molecules and the roles they
may play in PsA
The function of MHC molecules is to bind and present small
soluble peptides to T cells. The T-cell receptor (TCR)
inspects the complex of peptide and MHC, and if the fit is
sufficiently good this results in triggering of the TCR. The
biological roles played by class I molecules, such as are
encoded by HLA-B and  HLA-C alleles involved in PsA
susceptibility, differ greatly from those of class II molecules.
Class I molecules function in the immunosurveillance for intra-
cellular infection, typically by a virus, by presenting peptides
derived from cytoplasmic proteins to the TCR of CD8+
lineage T cells. Usually, the presence of a virally infected cell
results in it being killed by the CD8+ T cell.
Because the entire repertoire of T cells is selected in the
thymus on self peptides presented by the various self MHC
molecules of the person, the repertoire is latently self-
reactive. One explanation for the association of the HLA
alleles B*27 and B*39, and Cw*0602 with PsA susceptibility
is that the molecules encoded by these alleles recognize self-
peptides derived from proteins found in entheseal and
synovial sites. T-cell clones specific for these self-peptides
would be inappropriately activated, perhaps by dendritic
cells, and the activated state perpetuated by the continual
supply of self-peptides. This is the classic explanation of an
autoimmune disease as a consequence of driver clones, and
one would expect to recognize one or a few immunodominant
TCR sequences in the inflammatory infiltrate. Another
explanation that could be relevant to disease immunopatho-
genesis in the approximately 15% of PsA patients who have
HLA-B*27 is the nature of the HLA-B*27 molecule itself, as
initially suggested by the development of an arthrocutaneous
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Figure 2
Representation of the complex relationship between HLA susceptibility and psoriatic arthritis. The areas on the diagram are not exactly drawn to
scale. The right side of the diagram depicts the presence of the Cw*0602 allele in healthy people, its strong association with cutaneous psoriasis
susceptibility, and the fact that approximately 40% of those with psoriasis lack Cw*0602. The left side depicts the almost complete association of
B*27 with ankylosing spondylitis. Psoriatic arthritis, which includes psoriasis plus the musculoskeletal phenotype, is shown as the thick rimmed
circle. Both Cw*0602 and B*27 alleles contribute independently to psoriatic arthritis susceptibility. HLA, human leukocyte antigen.syndrome in rats transgenic for multiple copies of HLA-B*27
[6]. However, the large majority of PsA patients lack
HLA-B*27, and the development of PsA in association with
other HLA alleles is not accounted for by this mechanism.
The question of whether the disease has the characteristics
of a single peptide-driven T-cell response was addressed in
detailed studies of the nature of the population of T cells
found in the inflammatory joint fluid and in the synovium.
Lymphocyte phenotypic subpopulations can be readily
isolated from the joint fluid by fluorescence activated cell
sorting techniques. By isolating the RNA from the lymphocyte
subpopulations and determining the sequence of the T cell
receptors, the composition of the T cell repertoire can thus
be enumerated. The objective of these studies was to define
the extent to which the synovial infiltrate consists of one or a
few dominant expanded clones, suggesting antigen drive, or
conversely a large number of unrelated T cells that are not
clonally expanded.
The results of these analyses of the character of the
infiltrating T cells in PsA joint fluids and tissues [7,8] revealed
two features. The first is the presence of large expansions of
CD8+ T-cell clones implicating the adaptive immune
response in the disease. However, these expanded clones
lacked obvious common structural motifs that would imply the
presence of an antigen drive by one or a few peptide
autoantigens. This implies that there is some set of specific
events that triggers the adaptive immune response of clonal
expansion, but that this trigger is broader than usually
anticipated in the study of T-cell responses [9]. The finding of
different T-cell clones in different joints and at different times
is not consistent with a simple driver clone hypothesis, and it
suggests that a more intricate explanation is likely to account
for the puzzling combination of high expansion of a few
clones but the presence of a succession of different
dominant clones in time and space. The second feature was
the additional presence of a background of nonclonally
expanded polyclonal T cells, presumably reflecting the attrac-
tion of the T cells by chemokines. Only this latter polyclonal
population is markedly reduced by methotrexate therapy [8].
Co-stimulation of CD8+ T-cell clones by stress-induced
ligands
What could account for this clonal activation? Viruses use
various strategies to prevent their identification by the MHC
class I surveillance mechanism, and principal among these is
inhibition of class I MHC expression, which results in lowering
of surface class I MHC molecules on the surface of the
infected cell. To cope with this ancient viral strategy, higher
organisms have responded with the development of a lineage
of lymphocytes, the natural killer (NK) cells, which are
specialists in recognizing the absence of a normal amount of
MHC class I (‘missing self’). There are several kinds of NK
receptors, found on NK cells and also on memory effector
CD8+ T cells that are specialists in this recognition.
Additional NK receptors on memory effector CD8+ T cells,
along with those that recognize missing self, respond to
molecules induced by inflammatory cues or cellular stress.
These molecules replace the co-stimulatory molecule CD28
expressed on naïve T cells. We hypothesize that an over-
balance of stimulatory signals and triggering of the CD8+
T cells through NK receptor engagement is responsible for
triggering these T-cell clones. Triggering of NK cells by killer
immunoglobulin receptors, a subset of NK receptors, has
been proposed to be a feature of PsA [10]. Similarly,
triggering of memory effector cells produced in the response
to pathogens by Toll-like receptor ligands induces their
activation. Through this combination of innate immune
signals, a T-cell clone with relatively low affinity for a target
can be driven to respond to self-peptide.
Epidemiological studies support the potential role of infection
and trauma in the period before the development of PsA in
those with psoriasis [11]. Among 98 PsA patients and 163
control individuals, a number of environmental exposures
occurred that were associated with the onset of arthritis in
patients with psoriasis. These included rubella vaccination
and injury sufficient to require a medical consultation [11].
We consider one hypothetical explanation for the events in
the T-cell repertoire in PsA is that an array of T cells with
TCRs that have low specificity for peptides expressed in the
enthesis or the synovium are differentiated to memory effector
status and have their NK receptors engaged by these innate
ligands. The ongoing inflammation and stress induced by
infection or trauma compensate for the diminished TCR
affinity for self-peptides and the clones are triggered to
expand and continue to mediate synovial tissue injury.
Synovial tissue
The clinical criterion of tender and swollen joints reflecting
underlying synovitis is not specific for PsA, and at the
bedside it is often not distinguishable from the synovitis of
RA. This has two consequences. The first of these is that in
the clinic it may be difficult to determine the extent and nature
of joint involvement - a difficulty that is being resolved by
advances in imaging technology, as discussed below.
Second, the important question to address is whether the
synovial tissue in PsA exhibits any differentiating immuno-
logical features that would provide further insight into disease
pathogenesis.
Synovial tissue in PsA is characterized by a sublining infiltrate
with T cells and B cells, vascular proliferation and a relatively
thin lining layer of proliferating intimal synoviocytes. Indeed,
studies would suggest that the synovitis in PsA can be distin-
guished from RA, with quantitative differences in the features
of the tissue, although there are no unique pathological
hallmarks in either disease [12]. A recent study compared
synovial immunohistological features in spondyloarthropathy,
including PsA, with those of RA [13]. Spondyloarthropathy
tissue exhibited greater vascularity (P < 0.001) and neutrophil
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whereas lining layer thickness and the number of CD83+
dendritic cells were greater in RA (P < 0.05). In RA, 44% of
samples exhibited positive staining for intracellular citrullinated
proteins and 46% for MHC human cartilage gp39 peptide
complexes, whereas no staining for these markers was
observed in spondyloarthropathy samples (both P = 0.001).
The authors concluded that the synovial histopathology of
PsA resembles that of other spondyloarthropathy subtypes
and, like spondyloarthropathy, can be differentiated from RA
on the basis of these synovial features, suggesting that
peripheral synovitis in PsA belongs to the spondyloarthro-
pathy concept. This difference is consistent with the genetic
difference between RA and PsA emphasized in the studies
conducted by Ho and coworkers [5]
Synovial tissue in PsA is also characterized by expression of
pro-inflammatory cytokines, including IL-1, interferon-γ, tumour
necrosis factor (TNF)-α, IL-6, IL-12, IL-15, IL-17 and IL-18
[14-16]. Lymphoid aggregates are described and, as in RA,
occur in association with peripheral lymph node addressin-
positive high endothelial venules and with the expression of
the chemokines CXCL13 (C-X-C chemokine ligand 13) and
CCL21 (C-C chemokine ligand 21) [17]. In keeping with the
prominent vascular changes described both on arthroscopy
and on immunohistology, promoters of angiogenesis are also
upregulated, with expression of vascular endothelial growth
factor, its receptors Flt-1 and KDR, and of angiopoietin-1
and -2 [18].
Finally, Ritchlin and colleagues [19] showed that PsA
peripheral blood mononuclear cells readily formed osteo-
clasts  in vitro. In further immunohistochemical analysis of
subchondral bone and synovium, receptor activator of
nuclear factor-κB (RANK)-positive perivascular mononuclear
cells and osteoclasts were seen. RANK ligand expression
was dramatically upregulated in the synovial lining layer,
whereas osteoprotegerin (OPG) immunostaining was
restricted to the endothelium. Although bone erosions are
not a striking feature in all patients with PsA, a model for
understanding the pathogenesis of aggressive bone
erosions in PsA was proposed in which osteoclasts, derived
from TNF-α-activated peripheral blood mononuclear cells,
migrate to the inflamed synovium and subchondral bone,
where they are exposed to unopposed RANK ligand and
TNF-α, leading to osteoclastogenesis at the erosion front.
These findings have been confirmed by others [20]. How-
ever, the expression of RANK ligand and OPG was not
different between patients with nonpsoriatic spondylo-
arthropathy, those with psoriatic spondyloarthropathy and
those with RA; was not related to the degree of systemic or
local inflammation; and was not significantly modulated by
highly effective treatment with TNF-α blockers. Thus,
differences in the synovial expression of RANK ligand, OPG
and RANK cannot alone explain the radiological features
observed in PsA.
Taken together, the above data confirm a histological pattern
of joint inflammation similar to that in other spondyloarthro-
pathies but sharing cytokine, chemokine and osteoclast
promoting pathways found in chronic arthropathies. Despite
extensive analysis, specific diagnostic features have not
emerged though reproducible quantitative differences, in
particular related to vascularity and perhaps to neutrophil
infiltration, have been shown in several controlled studies.
The presence of common cytokine pathways certainly
explains the utility of several biologic therapies, such as TNF
blockers, in a number of chronic arthropathies. Differential
responses do occur, however, from which we may further
clarify the relative importance of certain pathways. For
example, targeting B cells in RA has proven efficacy, whereas
several reports have suggested that PsA patients may not
respond. Likewise, efalizumab - a humanized anti-CD11a
monoclonal antibody - is licensed for treatment of psoriasis
but appears to be ineffective in joint disease and may indeed
trigger joint features [21].
The answer to the question ‘What is PsA and how is it
diagnosed?’ remains of great importance. In the absence of
complete knowledge of the pathogenic mechanism, a
definitive laboratory test remains a distant goal. Accordingly,
there has been a considerable emphasis on the development
of syndromic criteria used for diagnosis and classification.
The recently developed CASPAR (ClASsification criteria for
Psoriatic ARthritis) criteria have largely been accepted by
those working in the area [22]. It will be important to validate
these criteria by determining whether they identify a genetically
and pathogenetically distinctive group of individuals who may
be expected to have a similar response to therapies.
Imaging
The detailed changes within the tissues and the underlying
pathogenic mechanisms that they signify are not readily
appreciated at the bedside, except in terms of their ultimate
consequences of painful, tender swollen and stiff joints.
However, imaging techniques, particularly those involving the
newer modalities of magnetic resonance imaging (MRI) and
ultrasound (US) provide a much more detailed charac-
terization of the tissue abnormalities.
The classic radiological features of PsA include new bone
formation at entheseal sites; bone resorption or osteolysis;
sacroiliitis, which is often asymmetrical; and the hallmark
pencil-in-cup type deformity, which results from a combina-
tion of new bone formation and osteolysis. These features
sometimes have diagnostic utility but none are specific, and
more often the radiological features in PsA are either minimal
or nonspecific. For example, erosions do occur in PsA but
less frequently than in RA, and the rate of development of
new erosions is much slower. In one study of early PsA, 47%
of patients had developed erosive disease at 2 years but the
number of erosions only increased from a mean of 1.2 (± 2.9)
to a mean of 3 (± 5.2) [23]. Although this increase was
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than are described in RA [24]. In contrast, new bone
formation is not a feature of RA.
Despite these differences from RA, clinical trials in PsA have
used instruments developed for RA (usually the Sharp score
or a modification thereof) when assessing radiological pro-
gression [25,26]. Taken together with the fact that joint
involvement in PsA is frequently oligoarticular and asym-
metrical, the use of such instruments to assess radiological
progression of PsA may not be appropriate. A radiological
scoring system developed for PsA that would reflect
differences both in joint distribution and radiological features
would be a welcome addition. Significant changes between
active treatment and placebo have been demonstrated in
clinical trials using these instruments borrowed from RA,
affording some utility to their application to PsA, although the
changes were less impressive than in RA.
Plain radiography certainly suggests that mechanisms of
joint damage in PsA differ from those in RA, with the
combination of new bone formation and erosions.
Preliminary studies have examined whether these differences
might be reflected in levels of soluble markers of bone
turnover. In a study of 62 patients (27 PsA and 35 RA), bone
alkaline phosphatase measurements, reflecting new bone
formation, were significantly higher in PsA than in RA (mean
T score: 1.42 versus 0.29; P < 0.05) [27]. These preliminary
results emphasize the importance of further studies aimed at
improving our understanding of the mechanisms of joint
damage in PsA.
The application of both US and MRI techniques to PsA has
also improved our understanding of disease mechanisms. A
recent study comparing US, MRI and plain radiography has
shown that both US and MRI are more sensitive for
visualization of inflammatory and destructive changes in
fingers and toes of patients with PsA [28]. US has
highlighted tendon and ligament involvement to an extent not
appreciated clinically. In a comparative study, 56% of
entheseal sites were abnormal on US as compared with 22%
detected clinically [29]. Examination of dactylitic digits using
US has demonstrated that both synovitis and tenosynovitis
contribute to disease features [30].
The use of MRI in PsA has emphasized the importance of
enthesitis with bone marrow oedema occurring at entheseal
sites [31]. Indeed, as a result of these observations, it has
been proposed that involvement of the enthesis is the primary
event in PsA, with synovial involvement occurring in a non-
specific manner [32]. Although this proposal has provoked
debate and is controversial, it has helped to focus research
on the enthesis and surrounding structures. It certainly could
be that disease is triggered after perturbation of the enthesis
and consequent exposure of entheseal-derived antigens to a
genetically primed immune system.
Entheseal changes have also been demonstrated in distal
interphalangeal (DIP) joints in PsA. Tan and coworkers [33]
compared the MRI and histological findings of the DIP joint in
10 patients with PsA, 10 with osteoarthritis and 10 normal
control individuals. In PsA, the dorsal capsular enthesis was
the epicentre of an inflammatory reaction. This extended to
involve the soft tissues adjacent to the nail in eight out of 10
PsA patients, but only in four of 10 cases with osteoarthritis
and in none of the normal fingers. The DIP joint capsule was
intimately linked with the nail complex on histology, with the
dorsal, volar and lateral aspects of the nail bed being
ensheathed in fibres extending from the entheses. This study
suggests that the nail is as much an integral part of the
enthesis organ as it is of the skin, which has implications for
enhanced understanding of the disease. In a further study of
13 PsA dactylitic digits, synovitis and soft tissue oedema
were the most frequent abnormalities, being present in 69%
of tender dactylitic digits, but bone oedema and flexor
tenosynovitis were also frequently seen [34].
Taken together, MRI studies in PsA have demonstrated
considerable capsular, entheseal and bony changes in PsA
that are quite different from those observed in RA [28]. These
imaging studies should be useful clinically in supporting a
diagnosis of PsA in an individual who presents only with
synovitis and psoriasis, and ultimately in clinical trials as an
index of response.
Current disease paradigm
The current paradigm of PsA places the lymphocyte, and in
particular the CD8+ T cell, at the root of the pathogenic
scheme. We accept this as a paradigm, and it is supported
by many observations, but it should be kept in mind that this
is not yet an established fact. The most likely implication of
the HLA associations is that the susceptible person’s T-cell
repertoire contains CD8+ T cells that can recognize peptides
derived from proteins in a still unknown triggering or target
cell, which we will arbitrarily designate a fibrocartilage cell.
These peptides are bound in the context of the MHC
molecules that confer susceptibility, which are expressed on
the surface of these triggering cells. The possible
mechanisms that lead to activation of this cell have been
discussed, but once activated the CD8+ T cells differentiate
to memory effector phenotype and acquire the ability to injure
target cells and release cytokines (for example, interferon-γ),
reprogramming gene expression of nearby cells and,
importantly, activating macrophages and vascular endothelium.
In considering the pathogenesis of PsA, the following
findings - referred to above - must be considered.
￿ Although there are strong heritability factors, PsA is
genetically not simply a subset of psoriasis. Additional
HLA and probably other genes contribute to disease
expression.
￿ Tissue involvement in PsA includes synovium and skin,
but MRI and US studies have highlighted the involvement
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synovial tissues.
￿ Angiogenesis, endothelial activation and neutrophil
infiltration are prominent features in PsA synovial tissue.
￿ In keeping with a class I HLA association, CD8+ T cells
predominate in synovial fluid with clonal expansion
identified. Antigen-driven T cells responses have proven
difficult to demonstrate.
￿ A striking feature in the tissue and joint fluid is the extreme
clonal expansion that persists even during treatment with
methotrexate. Paradoxically, however, there is no
evidence to indicate that one or a few structurally or
cognitively related T-cell clones drive the process, as is
the case for most autoimmune diseases. Rather, it
appears that a succession of different clones sequentially
dominate the repertoire of infiltrating T cells.
￿ Evidence is emerging that innate immune responses may
be triggered in PsA, with signalling through the Toll-like
receptors or NK receptors on memory effector T cells.
Indeed, there is evidence of nonclonally specific
infiltration or local expansion in the tissues and joint fluids.
However, it remains to be explained why only certain
clones are expanded in an inflammatory site.
In a summary illustration of the pathogenesis of PsA
(Figure 3), the key elements are the operation of environ-
mental triggers on a genetically and environmentally primed
host. Both non-MHC and MHC polymorphisms associated
with susceptibility predispose the TCR repertoire to auto-
reactivity and recognition of target self-peptides that are likely
to be expressed in target tissues. Additionally, prior response
to exogenous ligands encoded by pathogens results in
memory effector CD8+ T cells. Furthermore, prior episodes of
inflammation may similarly result in memory effector CD8+ T
cells that recognize stress-related self-antigens. The thres-
hold for triggering these memory effector T cells by cross-
reacting structures expressed or present in additional
encounters with pathogens or stress activates the CD8+
memory-effector T cells and initiates pathways of inflamma-
tion mediated by the expression of transcription factors such
as nuclear factor-κB and activator protein-1. This results in
the tissue response of PsA that is also manifest histopatho-
logically and by imaging techniques.
Therapy
In view of the still emerging picture of the details of these
biological events that are responsible for PsA, it is somewhat
premature to envision the ideal properties of drugs for use in
this disease. However, some more peripheral questions
appear to be answered in the negative, for instance a drug
that depletes CD4+ T cells is unlikely to be effective in
established PsA. Similarly, it would not be anticipated that a
B-cell-depleting agent such as rituximab would be
efficacious. There is also some question about the role that
tolerance-inducing agents would have, because the
fundamental T-cell alteration does not appear to be due to
one or a few autoimmune driver T-cell clones that could
readily be eliminated. Conversely, in view of the role played by
T-cell activation, proliferation and differentiation, and cytokine
release by T cells and macrophages, there is growing support
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Figure 3
Immunopathogenesis of psoriatic arthritis. A proposed model for psoriatic arthritis immunopathogenesis is illustrated in which a genetically primed
individual is exposed to a bacterial, stress, or entheseal-related peptide. This in turn activates the innate immune response, resulting in CD8
infiltration and chemokine/cytokine release. The process is amplified with angiogenesis and cellular infiltration of involved tissues. HLA and other
genes expressed may determine the exact pattern of tissue involvement. HLA, human leukocyte antigen; MHC, major histocompatibility complex;
NKR, natural killer cell receptor; TCR, T-cell receptor; TLR, Toll-like receptor.for agents that interfere with cytokine pathways, T-cell respon-
siveness and macrophage effects. Anti-TNF-α inhibition is an
example of this approach applied to macrophages. Agents
may be effective at the level of blocking naïve T-cell
activation, for example with agents such as abatacept, or
even more likely by blocking the response of NK and CD8+
effector T cells to innate immune danger signals.
Nonspecific
Methotrexate is the prototype of an effective nonspecific
agent. Some insight into the role of methotrexate in PsA was
provided by the TCR repertoire studies, in which clinical
response was accompanied by a significant depletion of the
polyclonal nonclonally expanded component of the T-cell
infiltrate, whereas the monoclonal expansions persisted, perhaps
accounting for the clinical rebound often seen after stopping
the drug. This suggested that the effect of methotrexate in
PsA was immunomodulatory, probably by diminishing chemo-
kine production [35], but certainly not tolerance induction.
Specific
The most significant advance in terms of therapy in PsA and
indeed in psoriasis is the development of anti-TNF-α
inhibition. These agents have been remarkably successful in
controlling all aspects of disease. Not all patients respond,
but some experience significant adverse effects and for most
patients treatment must be continued long term in order to
maintain the therapeutic effect. Having demonstrated clinical
efficacy, the pharmaceutical companies are no longer
supporting clinical trials in PsA of these existing anti-TNF-α
products, even though there are major unanswered questions
with regard to optimal usage. For example, we do not know
whether anti-TNF-α products work best in conjunction with
methotrexate, and neither do we know whether early
introduction of an anti-TNF-α product is more likely to result
in long-lasting and possibly drug-free remission. Finally, the
recent and unexpected reports of psoriasis developing for the
first time in patients on anti-TNF-α therapy are intriguing
[36,37]. Although the clinical psoriasis phenotype is often not
plaque but the more distinctive pustular form, the patho-
genesis of this response is currently obscure, but it further
emphasizes the heterogeneity of PsA and the involvement of
innate immune mechanisms.
Other specific therapies are showing promising initial
responses. These include anti-IL-23 and abatacept (cytotoxic
T-lymphocyte antigen 4-immunoglobulin), a naïve T-cell co-
stimulatory blocker that has been licensed for use in RA.
Improved understanding of pathogenic mechanism in PsA will
undoubtedly serve to open up additional therapeutic oppor-
tunities.
Conclusions
Current evidence suggests that PsA occurs in a genetically
primed individual in whom stress or entheseal-derived
antigens may perturb the immune response, resulting in
angiogenesis, T-cell infiltration and cytokine release. Further
detailed analysis testing this hypothesis is required.
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